Transdermal UV-curable hydrogel resin, hydrogel curing the same and cataplasm containing the same

Abstract

The present invention relates to a UV-curable hydrogel resin for transdermal administration, a hydrogel prepared using the UV-curable hydrogel resin, and a cataplasm prepared using the UV-curable hydrogel resin. More particularly, the present invention relates to a hydrogel resin with an optimal composition and composition ratio which allows increase in a water content of a hydrogel applied as a drug layer of a cataplasm, skin irritation mitigation, and crosslinking degree adjustment for adhesion control and is capable of controlling drug releasing property and transdermal absorbability, a hydrogel prepared by UV-hardening the hydrogel resin, and a cataplasm including the hydrogel.

Claims

1. A UV-curable hydrogel resin for cataplasm, comprising 5 to 35% by weight of a hydrophilic polymer, 0.1 to 10% by weight of an active ingredient, 12 to 40% by weight of a wetting agent, 0.5 to 25% by weight of a transdermal penetration facilitator, 0.01 to 2.0% by weight of a UV initiator, and 0.01 to 2.0% by weight of a UV crosslinking agent, and the remaining amount of a solvent, wherein the hydrophilic polymer comprises one or more selected from polyvinyl alcohol, polyvinyl pyrrolidone, a polyvinyl pyrrolidone/vinyl acetate copolymer, a vinyl ether/anhydric maleic acid copolymer, an isobutylene/anhydric maleic acid copolymer, a methoxyethylene/anhydric maleic acid copolymer, a methacrylic acid/butyl acrylate copolymer, alginate, hydroxyethyl methacrylate, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, ethyl cellulose, methyl cellulose, sodium carboxymethyl cellulose, a carboxyvinyl copolymer, polyethylene oxide, polyethylene glycol, polyacrylamide, polyhydroxyethyl methacrylate, polydioxolane, polyacrylic acid, sodium polyacrylate, polyvinyl acrylate, polyacryl acetate, and polyvinyl chloride, wherein the active ingredient comprises one or more selected from lidocaine, lidocaine hydrochloride, loxoprofen, loxoprofenate, ketoprofen, flurbiprofen, diclofenac, diclofenac salt, indomethacin, piroxicam, meloxicam, naproxen, ibuprofen, felbinac, menthol, glycol salicylate, methyl salicylate, pepper extracts, vanillyl nonylamide, butyl vinyl ether, centella asiatica, fusidic acid, fusidate, acrinol, Pueraria mirifica, heparin, heparinate, and allantoin, wherein the transdermal penetration facilitator comprises one or more selected from propylene glycol, dipropylene glycol, polyoxyethylene monooleate, polyglyceryl diisostearate, glycerin monooleate, polyoxyethylene sorbitan, N-methyl-2-pyrrolidone, N-carprylyl-2-pyrrolidone, N-dodecyl-2-pyrrolidone, lauryl pyrrolidone, isopropyl myristrate, sorbitan mono-oleate, propylene monolaurate, glycerol monolaurate, glycerol monooleate, and triacetin, wherein the wetting agent comprises one or more selected from glycerin, and sorbitol.

2. The UV-curable hydrogel resin according to claim 1, wherein the UV initiator comprises one or more selected from a ketone-based UV initiator, a thioxantone-based UV initiator, a benzophenone-based UV initiator, a coumarin-based UV initiator, a thiazoline-based UV initiator, a rhodanine-based UV initiator, and other UV initiators, wherein the ketone-based UV initiator comprises one or more of 1-hydroxy-cyclohexyl-phenyl-ketone, 2-hydroxy-2-methyl-1-phenyl-1-propanone, 2-hydroxy-1-[4-(2-hydroxyethoxy)phenyl]-2-methyl-1-propanone, 2-benzyl-2-(dimethylamino)-1-[4-(4-morpholinyl)phenyl]-1-butanone, and 2-methyl-1-[4-(methylthio)phenyl]-2-(4-morpholinyl)-1-propanone, the thioxantone-based UV initiator comprises one or more of thioxanthone, 2-isopropylthioxanthone, 2-chlorothioxanthone, 1-chloro-4-propoxythioxanthone, 2-dodecylthioxanthone, 2,4-diethylthioxanthone, 2,4-dimethylthioxanthone, 1-methoxy-carbonylthioxanthone, 2-ethoxycarbonylthioxanthone, 3-(2-methoxyethoxycarbonyl)-thioxanthone, 4-butoxycarbonylthioxanthone, 3-butoxycarbonyl-7-methylthioxanthone, 1-cyano-3-chlorothioxanthone, 1-ethoxycarbonyl-3-chlorothioxanthone, 1-ethoxycarbonyl-3-ethoxythioxanthone, 1-ethoxycarbonyl-3-aminothioxanthone, 1-ethoxycarbonyl-3-phenylsulfurylthioxanthone, 3,4-di[2-(2-methoxyethoxy)ethoxycarbonyl]-thioxanthone, 1,3-dimethyl-3-hydroxy-9H-thioxanthone-9-one 2-ehylhexylether, 1-ethoxycarbonyl-3-(1-methyl-1-morpholinoethyl)-thioxanthone, 2-methyl-6-dimethoxymethyl-thioxanthone, 2-methyl-6-(1,1-dimethoxybenzyl)-thioxanthone, 2-morpholinomethylthioxanthone, 2-methyl-6-morpholinomethylthioxanthone, N-allylthioxanthone-3,4-dicarboxamide, 1-phenoxythioxanthone, 6-ethoxycarbonyl-2-methoxythioxanthone, 6-ethoxycarbonyl-2-methylthioxanthone, thioxanthone-2-carboxylic acid polyethylene glycol ether, and 2-hydroxy-3-(3,4-dimethyl-9-oxo-9H-thioxanthone-2-2-yloxy)-N,N,N-trimethyl-1-propanaminiumchloride, the benzophenone-based UV initiator comprises one or more of benzophenone, 4-phenyl benzophenone, 4-methoxy benzophenone, 4,4′-dimethyl benzophenone, 4,4′-dichlorobenzophenone, 4,4′-bis(dimethylamino)-benzophenone, 4,4′-bis(diethylamino)benzophenone, 4,4′-bis(methylethylamino)benzophenone, 4,4′-bis(p-isopropylphenoxy)benzophenone, 3,3′-dimethyl-4-methoxy benzophenone, methyl-2-benzoylbenzoate, 4-(2-hydroxyethylthio)-benzophenone, 4-(4-tolylthio)benzophenone, 1-[4-4-benzoyl-phenylsulfanyl)-phenyl]-2-methyl-2(toluene-4-sulfonyl)-propane-1-one, 4-benzoyl-N,N,N-trimethylbenzenemethanaminium chloride, 2-hydroxy-3-(4-benzoyl-phenoxy)-N,N,N-trimethyl-1-propaneaminium chloride monohydrate, 4-(13-acryloyl-1,4,7,10,13-pentaoxatridecyl)-benzophenone, and 4-benzoyl-N,N-dimethyl-N-[2-(1-oxo-2-prophenyl)oxy]ethyl-benzenemethanaminium chloride, the coumarin-based UV initiator comprises one or more of coumarin 1, coumarin 2, coumarin 6, coumarin 7, coumarin 30, coumarin 102, coumarin 106, coumarin 138, coumarin 152, coumarin 153, coumarin 307, coumarin 314, coumarin 314T, coumarin 334, coumarin 337, coumarin 500, 3-benzoyl coumarin, 3-benzoyl-7-methoxycoumarin, 3-benzoyl-5,7-dimethoxycoumarin, 3-benzoyl-5,7-dipropoxycoumarin, 3-benzoyl-6,8-dichlorocoumarin, 3-benzoyl-6-chloro-coumarin, 3,3′-carbonyl-bis[5,7-di(propoxy)-coumarin], 3,3′-carbonyl-bis(7-methoxycoumarin), 3,3′-carbonyl-bis(7-diethylamino-coumarin), 3-isobutyroylcoumarin, 3-benzoyl-5,7-dimethoxy-coumarin, 3-benzoyl-5,7-diethoxy-coumarin, 3-benzoyl-5,7-dibutoxycoumarin, 3-benzoyl-5,7-di(methoxyethoxy)-coumarin, 3-benzoyl-5,7-di(allyloxy)coumarin, 3-benzoyl-7-dimethylaminocoumarin, 3-benzoyl-7-diethylaminocoumarin, 3-isobutyroyl-7-dimethylaminocoumarin, 3-benzoyl-7-diethylaminocoumarin, 3-isobutyroyl-7-dimethylaminocoumarin, 5,7-dimethoxy-3-(1-naphthoyl)-coumarin, 5,7-diethoxy-3-(1-naphthoyl)-coumarin, 3-benzoylbenzo[f]coumarin, 7-diethylamino-3-thienoylcoumarin, 3-(4-cyanobenzoyl)-5,7-dimethoxycoumarin, 3-(4-cyanobenzoyl)-5,7-dipropoxycoumarin, 7-dimethylamino-3-phenylcoumarin, and 7-diethylamino-3-phenylcoumarin, the thiazoline-based UV initiator comprises one or more of 3-(aroylmethylene)-thiazolines such as 3-methyl-2-benzoylmethylene-β-naphthothiazoline, 3-methyl-2-benzoylmethylene-benzothiazoline, and 3-ethyl-2-propionylmethylene-β-naphtholthiazoline, the rhodanine-based UV initiator comprises one or more of 4-dimethylaminobenzalrhodanine, 4-diethylaminobenzalrhodanine, and 3-ethyl-5-(3-octyl-2-benzothiazolinylidene)-rhodanine, and the other UV initiators comprise one or more selected from phenylacetophenone, hydroxy dimethyl acetophenone, 4,4′-bis(dimethylamino)benzyl, methylbenzoylformate, diphenyl (2,4,6-trimethylbenzoyl)-phosphine oxide, phenyl bis(2,4,6-trimethyl benzoyl), oxy-phenyl-acetic acid-2-[2-oxo-2-phenyl-acetoxy-ethoxy]-ethyl ester, oxy-phenyl-acetic acid-2-[2-hydroxy-ethoxy]-ethyl ester, 4-cyclopentadiene-1-yl) bis[2,6-difluoro-3-(1-H-pyrrole-1-yl)phenyl] titanium, 2-acetylnaphthalene, 2-naphthalaldehyde, iodonium salt, 9.10-anthraquinone, anthracene, pyrene, aminopyrene, perylene, phenanthrene, phenanthrenequinone, 9-fluorenone, dibenzosuberone, curcumin, xanthone, thiomichler's ketone, 2,5-bis(4-diethylaminobenzyllidene)cyclopentanone, 2-(4-dimethylamino-benzyllidene))-indan-1-one, α-(4-dimethylaminobenzyllidene))ketone such as 3-(4-dimethylamino-phenyl)-1-indan-5-yl-propenone, 3-phenylthiophthalimide, N-methyl-3,5-di(ethylthio)-phthalimide, N-methyl-3,5-di(ethylthio)-phthalimide, phenothiazine, methylphenothiazine, N-phenylglycine, amines such as triethanolamine and N-methyldiethanolamine, ethyl-p-dimethylaminobenzoate, 2-(dimethylamino)ethylbenzoate, 2-ethylhexyl-p-dimethylaminobenzoate, octyl-para-N,N-dimethylaminobenzoate, N-(2-hydroxyethyl)-N-methyl-para-toluidine, butoxyethyl 4-dimethylaminobenzoate, 4-dimethylaminoacetophenone, triethanolamine, methyldiethanolamine, dimethylaminoethanol, 2-(dimethylamino)ethyl benzoate, poly(propylene glycol)-4-(dimethylamino)benzoate, and michler's ketone.

3. The UV-curable hydrogel resin according to claim 1, wherein the UV crosslinking agent comprises one or more selected from benzyl methacrylate, lauryl methacrylate, isodecyl methacrylate, phenoxy methacrylate, 2-hydroxyethyl methacrylate, tetrahydro furfuryl methacrylate, cetyl(C16) methacrylate, stearyl methacrylate, methoxyPEG500 methacrylate, methoxyPEG600 methacrylate, methoxyPEG1000 methacrylate, 1,6-hexandiol dimethacrylate, butadiene dimethacrylate, neopentylglycol dimethacrylate, ethyleneglycol dimethacrylate, diethyleneglycol dimethacrylate, triethyleneglycol dimethacrylate, tetraethyleneglycol dimethacrylate, bisphenol A(EO)4 dimethacrylate, bisphenol A(EO)3 dimethacrylate, bisphenol A(EO)10 dimethacrylate, bisphenol A(EO)30 dimethacrylate, 1,3-butyleneglycol dimethacrylate, polyethylene glycol 400 dimethacrylate, polyethylene glycol 200 dimethacrylate, PPG1000(EO)15 dimethacrylate, PPG1000(EO)3 dimethacrylate, trimethylolpropane trimethacrylate, benzyl acrylate, lauryl acrylate, isodecyl acrylate, phenol(EO) acrylate, phenol(EO)2 acrylate, phenol(EO)4 acrylate, phenol(EO)6 acrylate, tetrahydro furfuryl acrylate, nonyl phenol(EO)4 acrylate, nonyl phenol(EO)8 acrylate, nonyl phenol(EO)2 acrylate, ethoxyethoxy ethyl acrylate, stearyl acrylate, 1,6-hexandiol diacrylate, 1,6-hexandiol(EO) diacrylate, butanediol diacrylate, hydroxy pivalic acid neopentyl glycol diacrylate, tripropylene glycol diacrylate, dipropylene glycol diacrylate, bisphenol A(EO)4 diacrylate, bisphenol A(EO)3 diacrylate, tricyclodecane dimethanol diacrylate, tetraethylene glycol diacrylate, polyethylene glycol 400 diacrylate, polyethylene glycol 200 diacrylate, polyethylene glycol 300 diacrylate, polyethylene glycol 600 diacrylate, polypropylene glycol 400 diacrylate, polypropylene glycol 750 diacrylate, bisphenol A(EO)10 diacrylate, bisphenol A(EO)30 diacrylate, tris(2-hydroxy ethyl)isocyanurate diacrylate, trimethylolpropane triacrylate, trimethylolpropane(EO)3 triacrylate, trimethylolpropane(EO)6 triacrylate, trimethylolpropane(EO)9 triacrylate, trimethylolpropane(EO)15 triacrylate, glycerin propoxylated triacrylate, pentaerythritol triacrylate, trimethylolpropane(PO)3 triacrylate, tris(2-hydroxy ethyl)isocyanurate triacrylate, pentaerythritol n-EO tetraacrylate, pentaerythritol tetraacrylate, dipentaerythritol pentaacrylate, dipentaerythritol hexaacrylate, caprolactone acrylate, O-phenylphenol EO acrylate, and methylene bisacrylamide.

4. The UV-curable hydrogel resin according to claim 1, wherein the UV-curable hydrogel resin has a pH of 3 to 9.

5. A UV-curable hydrogel for transdermal administration derived from the UV-curable hydrogel resin according to claim 1, wherein the UV-curable hydrogel exhibits an adhesion of 50 to 120 gf under a peel strength test according to an adhesion test method in the bandage section of the Korean Pharmacopoeia, wherein a cumulative skin permeation rate of the active ingredient of the UV-hardened hydrogel is 45 to 150 μg/cm.sup.2 and a skin permeation speed of the active ingredient of the UV-hardened hydrogel is 2.0 to 7.5 μ μg/cm.sup.2/hr for 24 hours, and wherein a cumulative skin permeation rate of the active ingredient and a skin permeation speed of the active ingredient are measured at 30 to 33° C. under a sink condition using a Franz diffusion cell having an effective area of 0.64 cm.sup.2 and an aqueous phase volume of 5.2 ml.

6. A cataplasm, comprising a drug layer that comprises the UV-curable hydrogel according to claim 5; and a drug support layer that comprises one or more selected from a polyurethane film, a porous film, a perforated film, a fabric, a nonwoven fabric, and a foam.

7. The cataplasm according to claim 6, wherein the drug layer has an average thickness of 20 to 2,000 μm, and the drug support layer has an average thickness of 7 to 500 μm.

8. The cataplasm according to claim 6, further comprising a peel layer, wherein the peel layer, the drug layer, and the drug support layer are sequentially stacked.

9. The cataplasm according to claim 8, wherein the peel layer has an average thickness of 15 μm to 500 μm and comprises a polymer film coated with a silicone resin or a fluorine resin, wherein the polymer film comprises one or more polymer compounds selected from polyester; polyvinyl chloride; polyvinylidenechloride; polyethyleneterephthalate; and copolymers thereof.

10. A method for providing anti-inflammation and analgesic effects in a subject in need thereof, comprising administering an effective amount of the cataplasm according to claim 6 to the subject.

11. A UV-curable hydrogel for transdermal administration derived from the UV-curable hydrogel resin according to claim 2, wherein the UV-curable hydrogel exhibits an adhesion of 50 to 120 gf under a peel strength test according to an adhesion test method in the bandage section of the Korean Pharmacopoeia, wherein a cumulative skin permeation rate of the active ingredient of the UV-hardened hydrogel is 45 to 150 μg/cm.sup.2 and a skin permeation speed of the active ingredient of the UV-hardened hydrogel is 2.0 to 7.5 μg/cm.sup.2/hr for 24 hours, and wherein a cumulative skin permeation rate of the active ingredient and a skin permeation speed of the active ingredient are measured at 30 to 33° C. under a sink condition using a Franz diffusion cell having an effective area of 0.64 cm.sup.2 and an aqueous phase volume of 5.2 ml.

12. A UV-curable hydrogel for transdermal administration derived from the UV-curable hydrogel resin according to claim 3, wherein the UV-curable hydrogel exhibits an adhesion of 50 to 120 gf under a peel strength test according to an adhesion test method in the bandage section of the Korean Pharmacopoeia, wherein a cumulative skin permeation rate of the active ingredient of the UV-hardened hydrogel is 45 to 150 μg/cm.sup.2 and a skin permeation speed of the active ingredient of the UV-hardened hydrogel is 2.0 to 7.5 μg/cm.sup.2/hr for 24 hours, and wherein a cumulative skin permeation rate of the active ingredient and a skin permeation speed of the active ingredient are measured at 30 to 33° C. under a sink condition using a Franz diffusion cell having an effective area of 0.64 cm.sup.2 and an aqueous phase volume of 5.2 ml.

13. A UV-curable hydrogel for transdermal administration derived from the UV-curable hydrogel resin according to claim 4, wherein the UV-curable hydrogel exhibits an adhesion of 50 to 120 gf under a peel strength test according to an adhesion test method in the bandage section of the Korean Pharmacopoeia, wherein a cumulative skin permeation rate of the active ingredient of the UV-hardened hydrogel is 45 to 150 μg/cm.sup.2 and a skin permeation speed of the active ingredient of the UV-hardened hydrogel is 2.0 to 7.5 μg/cm.sup.2/hr for 24 hours, and wherein a cumulative skin permeation rate of the active ingredient and a skin permeation speed of the active ingredient are measured at 30 to 33° C. under a sink condition using a Franz diffusion cell having an effective area of 0.64 cm.sup.2 and an aqueous phase volume of 5.2 ml.

Description

BEST MODE

(1) Hereinafter, the present invention is described in more detail.

(2) A method of preparing a cataplasm of the present invention includes a first step of preparing a hydrogel resin; a second step of coating the hydrogel resin on a peel film; a third step of stacking a support on the coated hydrogel resin; and a first step of irradiating the support with UV to harden the hydrogel resin.

(3) In the first step, the hydrogel resin may be prepared by stirring and crosslinking a mixture of a hydrophilic polymer, an active ingredient, a wetting agent, a solvent, a transdermal penetration facilitator, a UV initiator, and a UV crosslinking agent at room temperature (15° C. to 35° C.) at 150 to 1650 rpm for 5 to 12 hours such that the compositions are sufficiently dissolved in a solvent.

(4) The hydrophilic polymer of the hydrogel resin ingredients used in the first step serves to impart viscoelasticity to the hydrogel and maintain water content. The hydrophilic polymer may be included in an amount of 5 to 60% by weight, preferably 5 to 40% by weight, more preferably 8 to 35% by weight, based on a total weight of the hydrogel resin. Here, when the content of the hydrophilic polymer is less than 5% by weight, a water content and viscoelasticity of the hydrogel might not be maintained. On the other hand, when the content of the hydrophilic polymer is greater than 60% by weight, viscosity may too highly increase, which hinders the coating of the second step. In addition, crosslinking property may be greatly decreased.

(5) In addition, as the hydrophilic polymer, one or more selected from polyvinyl alcohol, polyvinyl pyrrolidone, a polyvinyl pyrrolidone/vinyl acetate copolymer, a vinyl ether/anhydric maleic acid copolymer, an isobutylene/anhydric maleic acid copolymer, a methoxyethylene/anhydric maleic acid copolymer, a methacrylic acid/butyl acrylate copolymer, alginate, hydroxyethyl methacrylate, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, ethyl cellulose, methyl cellulose, sodium carboxymethyl cellulose, a carboxyvinyl copolymer, polyethylene oxide, polyethylene glycol, polyacrylamide, polyhydroxyethyl methacrylate, polydioxolane, polyacrylic acid, sodium polyacrylate, polyvinyl acrylate, polyacryl acetate, polyvinyl chloride and polyacrylamide may be used. Preferably, one or more selected from polyvinyl pyrrolidone, a polyvinyl pyrrolidone/vinyl acetate copolymer, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl methacrylate, sodium polyacrylate, polyacrylic acid, sodium carboxymethyl cellulose, and polyacrylamide may be used. More preferably, the hydrophilic polymer may be prepared by mixing 5 to 100 parts by weight, preferably 10 to 50 parts by weight, of one or more selected from hydroxypropyl cellulose, sodium polyacrylate, polyacrylic acid, sodium carboxymethyl cellulose, and polyacrylamide with 100 parts by weight of polyvinylidone. As a particular example, a mixture of the hydrophilic polyvinyl pyrrolidone and sodium polyacrylate, a mixture of polyvinyl pyrrolidone and polyacrylic acid, a mixture of polyvinyl pyrrolidone and polyacrylamide, a mixture of polyvinyl pyrrolidone and polyvinyl alcohol, a mixture of polyvinyl pyrrolidone and sodium carboxymethyl cellulose, a mixture of polyvinyl pyrrolidone and hydroxyethyl cellulose, a mixture of polyvinyl pyrrolidone and hydroxypropyl cellulose, or a mixture of polyvinyl pyrrolidone and hydroxyethyl methacrylate may be used.

(6) In addition, the hydrophilic polymer may be a polymer treated with a publicly known crosslinking agent or polymer.

(7) As the active ingredient of the hydrogel resin ingredients used in the first step, an active ingredient, which has been used in the art, may be determined according to use of the hydrogel. Preferably, as the active ingredient, one or a mixture of two or more selected from lidocaine, lidocaine hydrochloride, loxoprofen, loxoprofenate, ketoprofen, flurbiprofen, diclofenac, diclofenac salt, indomethacin, piroxicam, meloxicam, naproxen, ibuprofen, felbinac, menthol, glycol salicylate, methyl salicylate, pepper extracts, vanillyl nonylamide, butyl vinyl ether, centella asiatica, fusidic acid, fusidate, acrinol, Pueraria mirifica, heparin, heparinate, and allantoin may be used. As a particular example, one or a mixture of two or more of lidocaine, lidocaine hydrochloride, loxoprofen, loxoprofenate, and the like having anti-inflammation and analgesic effects may be used.

(8) In addition, the active ingredient may be included in an amount of 0.1 to 15% by weight, preferably 1 to 10% by weight with respect to a total weight of the hydrogel resin. When the content of the active ingredient is less than 0.1% by weight, effect due to addition of the active ingredient might not be exhibited due to too small amount thereof. On the other hand, when the content of the active ingredient is greater than 15% by weight, the excessive active ingredient hinders crosslinking, which may cause problems in preparing the hydrogel.

(9) The wetting agent of the hydrogel resin ingredients used in the first step serves to maintain a wet state of a hydrogel, alleviate skin irritation, maintain constant cooling ability, and improve hydration of water. As the wetting agent, an agent generally used in the art may be used. Preferably, the wetting agent may include one or more selected from glycerin, 1,3-butylene glycol, propylene glycol, polypropylene glycol, sorbitol, mannitol, ethylene glycol, diethylene glycol, polyethylene glycol, and hyarulonic acid. More preferably, a mixture of glycerin and sorbitol mixed in a weight ratio of 1:0.2 to 0.5 may be used.

(10) In addition, the wetting agent may be included in an amount of 0.6 to 80% by weight, preferably 5 to 50% by weight, more preferably 12 to 40% by weight based on a total weight of the hydrogel resin. When the content of wetting agent is less than 0.6% by weight, a sufficient wet state of the hydrogel might not be maintained. On the other hand, when the content of wetting agent is greater than 80% by weight, the hydrogel might not be hardened.

(11) The solvent of the hydrogel resin ingredients used in the first step may be purified water, distilled water, or the like. The content of the solvent may be 13.5 to 90% by weight, preferably 18 to 70% by weight, more preferably 30 to 60% by weight, based on a total weight of the hydrogel resin.

(12) The transdermal penetration facilitator of the hydrogel resin ingredients used in the first step serves to promote transdermal absorption of the active ingredient and sustain efficacy thereof. The transdermal penetration facilitator may be included in an amount of 0.5 to 25% by weight, preferably 0.5 to 23% by weight, more preferably 1 to 20% by weight, based on a total weight of the hydrogel resin. When the content of the transdermal penetration facilitator is less than 0.5% by weight, transdermal absorption of the active ingredient in the hydrogel may be greatly decreased. On the other hand, when the content of the transdermal penetration facilitator is greater than 25% by weight, adhesion of the hydrogel may be decreased.

(13) As the transdermal penetration facilitator, only one or a mixture of two or more selected from propylene glycol, dipropylene glycol, polyethylene glycol, polyoxyethylene monooleate, polyglyceryl diisostearate, glycerin monooleate, polyoxyethylene sorbitan, N-methyl-2-pyrrolidone, N-carprylyl-2-pyrrolidone, N-dodecyl-2-pyrrolidone, lauryl pyrrolidone, lauryl alcohol, glycerol lauryl alcohol, oleyl alcohol, isopropyl myristrate, sorbitan mono-oleate, propylene monolaurate, propylene mono-oleate, oleoyl macrogolglyceride, oleic acid, lauroyl macrogol glyceride, linoleoyl macrogol glyceride, propylene glycol caprylate, propylene glycol caprate, sorbitan monostearate mono-oleate, glycerol monolaurate, glycerol monooleate, propylene glycol monolaurate, propylene glycol monocaprylate, sorbitan monolaurate, lauryl lactate, caprylic triglyceride, capric triglyceride, corn oil PEG-8 ester, corn oil PEG-6 ester, and triacetin may be used. Preferably, only one or a mixture of two or more selected from propylene glycol, dipropylene glycol, glycerin monooleate, polyoxyethylene sorbitan, N-methyl-2-pyrrolidone, sorbitan mono-oleate, isopropylmyristate, polyoxyethylene monooleate, glycerolmonooleate, propyleneglycolmonolaurate and polyglyceryl diisostearate may be used. More preferably, a mixture of propylene glycol and one selected from sorbitan mono-oleate, isopropylmyristate, polyoxyethylene monooleate, glycerolmonooleate, propyleneglycolmonolaurate, and polyglyceryl diisostearate mixed in a weight ratio of 1:0.03 to 0.5 may be used. In addition, more preferably, when the active ingredient is loxoprofen sodium and a salt thereof, a mixture of three or more selected from propylene glycol, glycerinmonooleate, glycerin monooleate, polyoxyethylene sorbitan, N-methyl-2-pyrrolidone, and laurylpyrrolidone may be used.

(14) The UV initiator of the hydrogel resin ingredients used in the first step serves to initiate crosslinking reaction, causing hydrogel formation. As the UV initiator, only one or a mixture of two or more selected from a ketone-based UV initiator, a thioxantone-based UV initiator, a benzophenone-based UV initiator, a coumarin-based UV initiator, a thiazoline-based UV initiator, a rhodanine-based UV initiator, and other UV initiators may be used. In addition, the content of the UV initiator may be 0.01 to 2.0% by weight, preferably 0.025 to 1.5% by weight, more preferably 0.1 to 1.0% by weight, based on a total weight of the hydrogel resin. When the content of the UV initiator is less than 0.01% by weight, hardening time due to UV irradiation may be too long, whereby marketability may be decreased. In addition, a hardened hydrogel may exhibit poor viscoelasticity. On the other hand, the content of the UV initiator is greater than 2% by weight, a hardening speed may be too fast, whereby it may be difficult to control a hardening speed and adhesion may be decreased.

(15) Examples of a UV initiator available in the present invention are particularly described as follows.

(16) As the ketone-based UV initiator, only one or a mixture of two or more selected from α-hydroxy ketones, such as 1-hydroxy-cyclohexyl-phenyl-ketone, 2-hydroxy-2-methyl-1-phenyl-1-propanone, and 2-hydroxy-1-[4-(2-hydroxyethoxy)phenyl]-2-methyl-1-propanone and α-amino ketones, such as 2-benzyl-2-(dimethylamino)-1-[4-(4-morpholinyl)phenyl]-1-butanone and 2-methyl-1-[4-(methylthio)phenyl]-2-(4-morpholinyl)-1-propanone may be used.

(17) As the thioxantone-based UV initiator, only one or a mixture of two or more selected from thioxanthone, 2-isopropylthioxanthone, 2-chlorothioxanthone, 1-chloro-4-propoxythioxanthone, 2-dodecylthioxanthone, 2,4-diethylthioxanthone, 2,4-dimethylthioxanthone, 1-methoxy-carbonylthioxanthone, 2-ethoxycarbonylthioxanthone, 3-(2-methoxyethoxycarbonyl)-thioxanthone, 4-butoxycarbonylthioxanthone, 3-butoxycarbonyl-7-methylthioxanthone, 1-cyano-3-chlorothioxanthone, 1-ethoxycarbonyl-3-chlorothioxanthone, 1-ethoxycarbonyl-3-ethoxythioxanthone, 1-ethoxycarbonyl-3-aminothioxanthone, 1-ethoxycarbonyl-3-phenylsulfurylthioxanthone, 3,4-di[2-(2-methoxyethoxy)ethoxycarbonyl]-thioxanthone, 1,3-dimethyl-3-hydroxy-9H-thioxanthone-9-one 2-ehylhexylether, 1-ethoxycarbonyl-3-(1-methyl-1-morpholinoethyl)-thioxanthone, 2-methyl-6-dimethoxymethyl-thioxanthone, 2-methyl-6-(1,1-dimethoxybenzyl)-thioxanthone, 2-morpholinomethylthioxanthone, 2-methyl-6-morpholinomethylthioxanthone, N-allylthioxanthone-3,4-dicarboxamide, 1-phenoxythioxanthone, 6-ethoxycarbonyl-2-methoxythioxanthone, 6-ethoxycarbonyl-2-methylthioxanthone, thioxanthone-2-carboxylic acid polyethylene glycol ether, and 2-hydroxy-3-(3,4-dimethyl-9-oxo-9H-thioxanthone-2-2-yloxy)-N,N,N-trimethyl-1-propanaminiumchloride may be used.

(18) As the benzophenone-based UV initiator, only one or a mixture of two or more selected from benzophenone, 4-phenyl benzophenone, 4-methoxy benzophenone, 4,4′-dimethyl benzophenone, 4,4′-dichlorobenzophenone, 4,4′-bis(dimethylamino)-benzophenone, 4,4′-bis(diethylamino)benzophenone, 4,4′-bis(methylethylamino)benzophenone, 4,4′-bis(p-isopropylphenoxy)benzophenone, 3,3′-dimethyl-4-methoxy benzophenone, methyl-2-benzoylbenzoate, 4-(2-hydroxyethylthio)-benzophenone, 4-(4-tolylthio)benzophenone, 1-[4-(4-benzoyl-phenylsulfanyl)-phenyl]-2-methyl-2(toluene-4-sulfonyl)-propane-1-one, 4-benzoyl-N,N,N-trimethylbenzenemethanaminium chloride, 2-hydroxy-3-(4-benzoyl-phenoxy)-N,N,N-trimethyl-1-propaneaminium chloride monohydrate, 4-(13-acryloyl-1,4,7,10,13-pentaoxatridecyl)-benzophenone, and 4-benzoyl-N,N-dimethyl-N-[2-(1-oxo-2-prophenyl)oxy]ethyl-benzenemethanaminium chloride may be used.

(19) As the coumarin-based UV initiator, only one or a mixture of two or more selected from coumarin 1, coumarin 2, coumarin 6, coumarin 7, coumarin 30, coumarin 102, coumarin 106, coumarin 138, coumarin 152, coumarin 153, coumarin 307, coumarin 314, coumarin 314T, coumarin 334, coumarin 337, coumarin 500, 3-benzoyl coumarin, 3-benzoyl-7-methoxycoumarin, 3-benzoyl-5,7-dimethoxycoumarin, 3-benzoyl-5,7-dipropoxycoumarin, 3-benzoyl-6,8-dichlorocoumarin, 3-benzoyl-6-chloro-coumarin, 3,3′-carbonyl-bis[5,7-di(propoxy)-coumarin], 3,3′-carbonyl-bis(7-methoxycoumarin), 3,3′-carbonyl-bis(7-diethylamino-coumarin), 3-isobutyroylcoumarin, 3-benzoyl-5,7-dimethoxy-coumarin, 3-benzoyl-5,7-diethoxy-coumarin, 3-benzoyl-5,7-dibutoxycoumarin, 3-benzoyl-5,7-di(methoxyethoxy)-coumarin, 3-benzoyl-5,7-di(allyloxy)coumarin, 3-benzoyl-7-dimethylaminocoumarin, 3-benzoyl-7-diethylaminocoumarin, 3-isobutyroyl-7-dimethylaminocoumarin, 3-benzoyl-7-diethylaminocoumarin, 3-isobutyroyl-7-dimethylaminocoumarin, 5,7-dimethoxy-3-(1-naphthoyl)-coumarin, 5,7-diethoxy-3-(1-naphthoyl)-coumarin, 3-benzoylbenzo[f]coumarin, 7-diethylamino-3-thienoylcoumarin, 3-(4-cyanobenzoyl)-5,7-dimethoxycoumarin, 3-(4-cyanobenzoyl)-5,7-dipropoxycoumarin, 7-dimethylamino-3-phenylcoumarin, and 7-diethylamino-3-phenylcoumarin may be used.

(20) As the thiazoline-based UV initiator, only one or a mixture of two or more selected from 3-(aroylmethylene)-thiazoline, 3-methyl-2-benzoylmethylene-β-naphthothiazoline, 3-methyl-2-benzoylmethylene-benzothiazoline, and 3-ethyl-2-propionylmethylene-β-naphtholthiazoline may be used.

(21) As the rhodanine-based UV initiator, only one or a mixture of two or more selected from 4-dimethylaminobenzalrhodanine, 4-diethylaminobenzalrhodanine, and 3-ethyl-5-(3-octyl-2-benzothiazolinylidene)-rhodanine may be used.

(22) In addition, as the other UV initiators, only one or a mixture of two or more selected from acetophenone, 3-methoxyacetophenone, 4-phenylacetophenone, α-dimethoxy-α-phenylacetophenone, hydroxy dimethyl acetophenone, benzyl, 4,4′-bis(dimethylamino)benzyl, methylbenzoylformate, diphenyl (2,4,6-trimethylbenzoyl)-phosphine oxide, phenyl bis(2,4,6-trimethyl benzoyl), oxy-phenyl-acetic acid-2-[2-oxo-2-phenyl-acetoxy-ethoxy]-ethyl ester, oxy-phenyl-acetic acid-2-[2-hydroxy-ethoxy]-ethyl ester, 4-cyclopentadiene-1-yl) bis[2,6-difluoro-3-(1-H-pyrrole-1-yl)phenyl] titanium, 2-acetylnaphthalene, 2-naphthalaldehyde, iodonium salt, dicylic acid derivatives, 9.10-anthraquinone, anthracene, pyrene, aminopyrene, perylene, phenanthrene, phenanthrenequinone, 9-fluorenone, dibenzosuberone, curcumin, xanthone, thiomichler's ketone, e.g., α-(4-dimethylaminobenzyllidene))ketone such as 2,5-bis(4-diethylaminobenzyllidene)cyclopentanone, 2-(4-dimethylamino-benzyllidene))-indan-1-one, or 3-(4-dimethylamino-phenyl)-1-indan-5-yl-propenone, 3-phenylthiophthalimide, N-methyl-3,5-di(ethylthio)-phthalimide, N-methyl-3,5-di(ethylthio)-phthalimide, phenothiazine, methylphenothiazine, an amine such as, for example, N-phenylglycine, triethanolamine or N-methyldiethanolamine, ethyl-p-dimethylaminobenzoate, 2-(dimethylamino)ethylbenzoate, 2-ethylhexyl-p-dimethylaminobenzoate, octyl-para-N,N-dimethylaminobenzoate, N-(2-hydroxyethyl)-N-methyl-para-toluidine, butoxyethyl 4-dimethylaminobenzoate, 4-dimethylaminoacetophenone, triethanolamine, methyldiethanolamine, dimethylaminoethanol, 2-(dimethylamino)ethyl benzoate, polypropylene glycol)-4-(dimethylamino)benzoate, and michler's ketone may be used.

(23) The UV crosslinking agent of the hydrogel resin ingredients used in the first step serves to adjust a crosslinking degree of a hydrogel to control adhesion and elasticity of the hydrogel. The content of the UV crosslinking agent may be 0.01 to 2% by weight, preferably 0.025 to 2% by weight, more preferably 0.025 to 1.5% by weight, based on a total weight of the hydrogel resin. When the content of the UV crosslinking agent is less than 0.01% by weight, a UV-cured hydrogel may exhibit too low viscoelasticity. On the other hand, when the content of the UV crosslinking agent is greater than 2% by weight, adhesion may be rather decreased.

(24) In addition, as the UV crosslinking agent, only one or a mixture of two or more selected from benzyl methacrylate, lauryl methacrylate, isodecyl methacrylate, phenoxy methacrylate, 2-hydroxyethyl methacrylate, tetrahydro furfuryl methacrylate, cetyl(C16) methacrylate, stearyl methacrylate, methoxyPEG500 methacrylate, methoxyPEG600 methacrylate, methoxyPEG1000 methacrylate, 1,6-hexandiol dimethacrylate, butadiene dimethacrylate, neopentylglycol dimethacrylate, ethyleneglycol dimethacrylate, diethyleneglycol dimethacrylate, triethyleneglycol dimethacrylate, tetraethyleneglycol dimethacrylate, bisphenol A(EO)4 dimethacrylate, bisphenol A(EO)3 dimethacrylate, bisphenol A(EO)10 dimethacrylate, bisphenol A(EO)30 dimethacrylate, 1,3-butyleneglycol dimethacrylate, polyethylene glycol 400 dimethacrylate, polyethylene glycol 200 dimethacrylate, PPG1000(EO)15 dimethacrylate, PPG1000(EO)3 dimethacrylate, trimethylolpropane trimethacrylate, benzyl acrylate, lauryl acrylate, isodecyl acrylate, phenol(EO) acrylate, phenol(EO)2 acrylate, phenol(EO)4 acrylate, phenol(EO)6 acrylate, tetrahydro furfuryl acrylate, nonyl phenol(EO)4 acrylate, nonyl phenol(EO)8 acrylate, nonyl phenol(EO)2 acrylate, ethoxyethoxy ethyl acrylate, stearyl acrylate, 1,6-hexandiol diacrylate, 1,6-hexandiol(EO) diacrylate, butanediol diacrylate, hydroxy pivalic acid neopentyl glycol diacrylate, tripropylene glycol diacrylate, dipropylene glycol diacrylate, bisphenol A(EO)4 diacrylate, bisphenol A(EO)3 diacrylate, tricyclodecane dimethanol diacrylate, tetraethylene glycol diacrylate, polyethylene glycol 400 diacrylate, polyethylene glycol 200 diacrylate, polyethylene glycol 300 diacrylate, polyethylene glycol 600 diacrylate, polypropylene glycol 400 diacrylate, polypropylene glycol 750 diacrylate, bisphenol A(EO)10 diacrylate, bisphenol A(EO)30 diacrylate, tris(2-hydroxy ethyl)isocyanurate diacrylate, trimethylolpropane triacrylate, trimethylolpropane(EO)3 triacrylate, trimethylolpropane(EO)6 triacrylate, trimethylolpropane(EO)9 triacrylate, trimethylolpropane(EO)15 triacrylate, glycerin propoxylated triacrylate, pentaerythritol triacrylate, trimethylolpropane(PO)3 triacrylate, tris(2-hydroxy ethyl)isocyanurate triacrylate, pentaerythritol n-EO tetraacrylate, pentaerythritol tetraacrylate, dipentaerythritol pentaacrylate, dipentaerythritol hexaacrylate, caprolactone acrylate, O-phenylphenol EO acrylate, and methylene bisacrylamide may be used. Preferably, only one or a mixture of two or more selected from methylene bisacrylamide, 2-hydroxyethyl methacrylate, ethyleneglycol dimethacrylate, 1,3-butyleneglycol dimethacrylate, polyethyleneglycol 400 dimethacrylate, tripropyleneglycol diacrylate, and tetraethyleneglycol diacrylate may be used.

(25) The second step of the method of preparing a cataplasm according to the present invention is a process of coating (or spreading) the hydrogel resin, which has been prepared in the first step, on a peel film. This coating may be performed by a general method used in the art.

(26) In addition, the peel film is separated from a cataplasm immediately before attaching the cataplasm to the skin such that a drug layer is attached to the skin. An average thickness of the peel film (peel layer) is advantageously 15 μm to 500 μm, preferably 20 μm to 300 μm, in terms of easy peeling or ease of production.

(27) In addition, the peel film is a polymer film coated with a silicone resin or a fluorine resin. The polymer film may include only one polymer compound or a mixture of two or more polymer compounds selected from polyester; polyvinyl chloride; polyvinylidenechloride; polyethyleneterephthalate; and a copolymer thereof.

(28) The third step of the method of preparing a cataplasm of the present invention is a process of stacking a support on the hydrogel resin that is coated on the peel film. The support functions as a drug support layer of a cataplasm. As the support, only one or a mixture of two or more selected from a polyurethane film, a porous film, a perforated film, a fabric, a nonwoven fabric, and a foam may be used. In addition, the support may have an average thickness of 7 μm to 500 μm, preferably 50 μm to 250 μm. When the average thickness of the support is less than 7 μm, sufficient mechanical properties might not be secured due to too thin thickness, whereby the support might not function as a support for a hardened hydrogel (drug layer). When the average thickness of the support is greater than 500 μm, wearability may be decreased due to excessive thickness. Therefore, it is preferred to use a support having a thickness within the range.

(29) The fourth step of the method of preparing a cataplasm of the present invention is a process of stacking a peel film, a hydrogel resin coating layer, and a support and then irradiating the support with UV to harden the hydrogel resin between the peel film and the support, thereby forming a hydrogel (drug layer). Here, the UV irradiation may be performed at an intensity of 2,000 to 8,000 mW/cm.sup.2 for 3 to 10 minutes, preferably at 2,500 to 5,000 mW/cm.sup.2 for 3 to 10 minutes.

(30) An average thickness of the UV-hardened hydrogel is not specifically limited and may be preferably 20 μm to 2,000 μm, more preferably 40 μm to 1,000 μm.

(31) In addition, a cumulative skin permeation rate of the active ingredient of the UV-hardened hydrogel, which is measured at 30 to 33° C. under a sink condition using a Franz diffusion cell having an effective area of 0.64 cm.sup.2 and an aqueous phase volume of 5.2 ml, may be 40 to 160 μg/cm.sup.2, preferably 45 to 150 μg/cm.sup.2, more preferably 50 to 150 μg/cm.sup.2.

(32) In addition, a skin permeation speed of the active ingredient of the UV-hardened hydrogel, which is measured at 30 to 33° C. under a sink condition using a Franz diffusion cell having an effective area of 0.64 cm.sup.2 and an aqueous phase volume of 5.2 ml, may be 1.0 to 7.5 μg/cm.sup.2/hr, preferably 1.0 to 7.0 μg/cm.sup.2/hr, more preferably 1.0 to 6.8 μg/cm.sup.2/hr. Therefore, the UV-hardened hydrogel may have an excellent skin permeation speed.

(33) In addition, the UV-hardened hydrogel, which is subjected to a peel strength test according to an adhesion test of the bandage section of the Korean Pharmacopoeia, may exhibits an adhesion of 40 gf to 150 gf, preferably 50 gf to 150 gf, more preferably 60 gf to 150 gf. Therefore, the UV-hardened hydrogel may have excellent adhesion to the skin.

(34) A cataplasm prepared according to the method of the present invention includes a peel layer; a drug layer including a UV-curable hydrogel for transdermal administration; and a drug support layer. Here, the peel layer is the aforementioned peel film, and is removed upon application of the cataplasm to the skin. In addition, the drug support layer corresponds to the aforementioned support.

(35) Particular use of the cataplasm of the present invention may depend upon an active ingredient in the drug layer. For example, a cataplasm for anti-inflammation or analgesic effects may be prepared upon use of lidocaine, lidocaine hydrochloride, loxoprofen, loxoprofenate, or the like as the active ingredient.

(36) Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the scope of the present invention is not limited to the ranges exemplified by the following examples.

EXAMPLE

Example 1

Preparation of Hydrogel Resin

(37) A hydrogel resin was prepared by mixing, stirring, and completely dissolving 15% by weight of polyvinyl pyrrolidone, 0.25% by weight of flurbiprofen, 28.75% by weight of glycerin, 10% by weight of sorbitol, 15% by weight of propylene glycol, 0.01% by weight of 1-hydroxy-cyclohexyl-phenyl-ketone, 0.2% by weight of methylene bisacrylamide, and 30.79% by weight of purified water.

Examples 2 to 62

(38) Hydrogel resins were prepared to have compositions and composition ratios summarized in Tables 1 to 7 below in the same manner as in Example 1.

(39) TABLE-US-00001 TABLE 1 Examples Classification (% by weight) 1 2 3 4 5 6 7 8 9 10 Hydrophilic Polyvinyl 15 15 15 15 15 15 15 15 15 15 polymer pyrrolidone Active Flurbiprofen 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 ingredient Wetting Glycerin 28.75 28.75 28.75 28.75 28.75 28.75 28.75 28.75 28.75 28.75 agent Sorbitol 10 10 10 10 10 10 10 10 10 10 Transdermal Propylene glycol 15 15 15 15 15 15 15 15 15 15 penetration facilitator Solvent Purified water 30.79 30.7 29.8 30.79 30.7 29.8 30.3 29.8 30.3 29.8 UV 1-hydroxy- 0.01 0.1 1 — — — — — — — initiator cyclohexyl-phenyl- ketone Benzophenone — — — 0.01 0.1 1 — — — — Methylbenzoylformate — — — — — — 0.5 1 Phosphine oxide, — — — — — — — — 0.5 1 phenyl bis(2,4,6- trimethylbenzoyl) 2-hydroxy-2- — — — — — — — — — — methyl-1-phenyl-1- propanone UV Methylene 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 crosslinking bisacrylamide agent

(40) TABLE-US-00002 TABLE 2 Examples Classification (% by weight) 11 12 13 14 15 16 17 18 19 20 Hydrophilic Polyvinyl 15 15 15 15 10 20 15 15 15 15 polymer pyrrolidone Active Flurbiprofen 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 ingredient Wetting Glycerin 28.75 28.75 28.75 28.75 28.75 28.75 38.75 78.75 28.75 28.75 agent Sorbitol 10 10 10 10 10 10 10 10 10 10 Transdermal Propylene glycol 15 15 15 15 15 15 15 15 15 15 penetration facilitator Solvent Purified water 30.3 29.8 30.6 29.8 35.6 25.6 20.6 40.6 30.5 30.7 UV 1-hydroxy- — — 0.1 0.5 0.1 0.1 0.1 0.1 0.1 0.1 initiator cyclohexyl-phenyl- ketone Benzophenone — — 0.1 0.5 0.1 0.1 0.1 0.1 0.1 0.1 Methylbenzoylformate — — — — — — — — — — Phosphine oxide, — — — — — — — — — — phenyl bis(2,4,6- trimethylbenzoyl) 2-hydroxy-2- 0.5 1 — — — — — — — — methyl-1-phenyl-1- propanone UV Methylene 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.1 crosslinking bisacrylamide agent

(41) TABLE-US-00003 TABLE 3 Examples Classification (% by weight) 21 22 23 24 25 26 27 28 29 30 Hydrophilic Polyvinyl 15 15 15 15 15 15 15 15 15 15 polymer pyrrolidone Active Flurbiprofen 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 ingredient Wetting Glycerin 25 25 25 25 25 25 25 25 25 25 agent Sorbitol 13.75 13.75 13.75 13.75 13.75 13.75 13.75 13.75 13.75 13.75 Transdermal Propylene glycol 15 15 15 15 15 15 15 15 15 15 penetration facilitator Solvent Purified water 30.8 30.35 29.85 28.85 30.8 29.85 28.85 30.6 30.8 29.85 UV Benzophenone 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 initiator UV Methylene 0.05 0.5 1 2 — — — — — crosslinking bisacrylamide agent 2-hydroxyethyl — — — — 0.05 1 2 — — methacrylate Ethyleneglycol — — — — — — — 0.25 0.05 1 dimethacrylate 1,3- — — — — — — — — — — butyleneglycol dimethacrylate Polyethylene — — — — — — — — — — glycol 400 dimethacrylate Tripropyleneglycol — — — — — — — — — — diacrylate Tetraethyleneglycol — — — — — — — — — — diacrylate

(42) TABLE-US-00004 TABLE 4 Classification (% by Examples weight) 31 32 33 34 35 36 37 38 39 40 41 Hydrophilic Polyvinyl 15 15 15 15 15 15 15 15 15 15 15 polymer pyrrolidone Active Lidocaine 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 ingredient Wetting Glycerin 25 25 25 25 25 25 25 25 25 25 25 agent Sorbitol 13.75 13.75 13.75 13.75 13.75 13.75 13.75 13.75 13.75 13.75 13.75 Transdermal Propylene 15 15 15 15 15 15 15 15 15 15 15 penetration glycol facilitator Solvent Purified water 29.35 28.85 30.8 29.85 28.85 30.8 29.85 28.85 30.8 29.85 28.85 UV Benzophenone 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 initiator UV Methylene — — — — — — — — — — — crosslinking bisacrylamide agent 2-hydroxyethyl — — — — — — — — — — — methacrylate Ethyleneglycol — — — — — — — — — — — dimethacrylate 1,3- 1.5 2 — — — — — — — — — butyleneglycol dimethacrylate Polyethylene — — 0.05 1 2 — — — — — — glycol 400 dimethacrylate Tripropylene — — — — — 0.05 1 2 — — — glycol diacrylate Tetraethyleneglycol — — — — — — — — 0.05 1 2 diacrylate

(43) TABLE-US-00005 TABLE 5 Examples Classification (% by weight) 42 43 44 45 46 47 Hydrophilic Polyvinyl pyrrolidone 4 7 10 15 20 25 polymer Active ingredient Flurbiprofen 0.25 0.25 0.25 0.25 0.25 0.25 Wetting agent Glycerin 25 25 25 15 10 5 Sorbitol 13.75 13.75 13.75 13.75 13.75 8.75 Transdermal Propylene glycol 15 15 15 10 10 10 penetration facilitator Solvent Purified water 41.5 38.5 35.5 45.5 45.5 50.5 UV initiator Benzophenone 0.15 0.15 0.15 0.15 0.15 0.15 UV crosslinking Methylene 0.25 0.25 0.25 0.25 0.25 0.25 agent bisacrylamide pH regulator Tartaric acid 0.1 0.1 0.1 0.1 0.1 0.1

(44) TABLE-US-00006 TABLE 6 Examples Classification (% by weight) 48 49 50 51 52 53 54 55 56 Hydrophilic Polyvinyl 10 10 10 10 10 10 10 10 10 polymer pyrrolidone Polyacrylic acid 1 3 5 0 0 0 0 0 0 Polyacrylamide 0 0 0 1 3 5 0 0 0 Hydroxypropyl 0 0 0 0 0 0 1 3 5 cellulose Active Flurbiprofen 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 ingredient Wetting agent Glycerin 15 10 10 15 10 10 15 10 10 Sorbitol 13.75 13.75 8.75 13.75 13.75 8.75 13.75 13.75 8.75 Transdermal Propylene glycol 15 10 10 15 10 10 15 10 10 penetration facilitator Solvent Purified water 44.6 52.6 55.6 44.6 52.6 55.6 44.6 52.6 55.6 UV initiator Benzophenone 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 UV Ethyleneglycol 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 crosslinking dimethacrylate agent

(45) TABLE-US-00007 TABLE 7 Examples Classification (% by weight) 57 58 59 60 61 62 Hydrophilic Polyvinyl pyrrolidone 15 15 15 15 15 15 polymer Active ingredient Flurbiprofen 0.25 0.25 0.25 0.25 0.25 0.25 Wetting agent Glycerin 25 25 25 25 25 25 Sorbitol 13.75 13.75 13.75 13.75 13.75 13.75 Transdermal Propylene glycol 15 15 15 15 15 15 penetration Sorbitanmonooleate 1 — — — — — facilitator Isopropylmyristate — 1 — — — — Polyoxyethylene — — 1 — — — monooleate Glycerolmonooleate — — — 1 — — Propyleneglycolmonolaurate — — — — 1 — Polyglyceryl diisostearate — — — — — 1 Solvent Purified water 29.6 29.6 29.6 29.6 29.6 29.6 UV initiator Benzophenone 0.15 0.15 0.15 0.15 0.15 0.15 UV crosslinking Methylene bisacrylamide 0.25 0.25 0.25 0.25 0.25 0.25 agent

Examples 63 to 70

(46) Hydrogel resins were prepared to have compositions and composition ratios of Table 8 in the same manner as in Example 1 except that a different active ingredient was used.

(47) TABLE-US-00008 TABLE 8 Examples Classification (% by weight) 63 64 65 66 67 68 69 70 Hydrophilic Polyvinyl 15 15 15 15 15 15 15 15 polymer pyrrolidone Active Loxoprofen 1.5 1.5 1.5 1.5 1.5 1.5 1.5 2 ingredient sodium Wetting agent Glycerin 28 28 28 28 28 28 28 33 Sorbitol 7 7 7 7 7 7 7 5 Transdermal Triacetin — — 2 — 2 1.5 — — penetration Propylene 28 28 28 28 28 28 28 28.53 facilitator glycol Glycerin 2 — — — — — 1 1 monooleate N-methyl-2- 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 pyrrolidone (NMP) Polyoxyethylene 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.2 sorbitan Lauryl — 2 — — 1 1.5 1 1 pyrrolidone Solvent Purified water 16.78 16.78 16.78 16.78 16.78 16.78 16.78 13 UV initiator Benzophenone 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.1 UV Glycol HEMA- 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.15 crosslinking methacrylate agent pH regulator Tartaric acid 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Preservative Methylparaben 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.12 Flavoring L-menthol 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 agent

Examples 71 to 74

(48) Hydrogel resins were prepared to have compositions and composition ratios of Table 9 in the same manner as in Example 1 except that different active ingredient was used.

(49) TABLE-US-00009 TABLE 9 Examples Classification (% by weight) 71 72 73 74 Hydrophilic Polyvinyl pyrrolidone 10 10 10 10 polymer Active ingredient Flurbiprofen 1 1 1.2 1.2 Wetting agent Glycerin 30 31 31 30 Sorbitol 10 10 10 10 Transdermal Propylene glycol 23 23 23 23 penetration Sorbitanmonooleate 1 1 1 1 facilitator Lauryl pyrrolidone 1 1 1 1 Solvent Purified water 22.63 21.68 21.5 22.53 UV initiator Benzophenone 0.12 0.07 0.05 0.02 UV crosslinking Glycol HEMA- 0.25 0.25 0.25 0.25 agent methacrylate Flavoring agent Menthol 1 1 1 1

Comparative Example 1

(50) A hydrogel resin was prepared to have a composition and a composition ratio summarized in Table 10 below. A hydrogel resin having the composition of Table 10 below was hardened by metal complex ion crosslinking. A hardening time of the hydrogel resin was 14 days.

(51) TABLE-US-00010 TABLE 10 Classification (% by weight) Comparative Example 1 Flurbiprofen 0.5 Glycerin 19.00 Sorbitol 20.00 Polyacrylate solution 10.00 Sodium polyacrylate 5.00 Sodium carboxymethyl cellulose 5.00 Propylene glycol 5.00 Urea 3.00 Tartaric acid 1.50 Dihydroxy aluminum aminoacetate 0.25 Purified water 30.75

Comparative Examples 2 to 10

(52) Hydrogel resins were prepared to have compositions and composition ratios of Table 11 below in the same manner as in Example 1.

(53) TABLE-US-00011 TABLE 11 Comparative Examples Classification 2 3 4 5 6 7 8 Hydrophilic Polyvinyl 3 65 15 20 17 15 15 polymer pyrrolidone Active Flurbiprofen 4 4 17 5 5 4 4 ingredient Wetting agent Glycerin 25 10 25 0.2 25 25 25 Sorbitol 10 5 10 0.2 10 10 10 Transdermal Lauryl 15 10 15 30 0 15 15 penetration pyrrolidone facilitator Solvent Purified water 44.6 5.6 17.6 44.2 42.6 30.75 30.85 UV initiator 1-hydroxy- 0.15 0.15 0.15 0.15 0.15 0 0.15 cyclohexyl- phenyl-ketone UV Methylene 0.25 0.25 0.25 0.25 0.25 0.25 0 crosslinking bisacrylamide agent

Preparation Example 1

Preparation of Cataplasm

(54) The hydrogel solution prepared in Example 1 was coated on one surface of a polyester film (thickness: 75 μm) coated with a silicone resin. The hydrogel resin coating layer was covered with a nonwoven fabric, and then hardened by UV-irradiating for 4 minutes, thereby preparing a cataplasm in which a peel layer (peel film), a drug layer (hydrogel) and a drug support layer (nonwoven fabric) were stacked and integrated. The hydrogel was prepared to have an average thickness of 500 μm.

Preparation Examples 2 to 74 and Comparative Preparation Examples 2 to 10

(55) Cataplasms of Preparation Examples 2 to 74 were prepared in the same manner as in Example 1, except that the hydrogel resins of Examples 2 to 74 were respectively used instead of the hydrogel resin of Example 1.

Comparative Preparation Example 1

(56) A cataplasm was prepared in the same manner as in Example 1, except that hardening by metal complex ionic bonding, instead of UV irradiation, was performed by allowing to stand at room temperature (25° C. to 27° C.) for 14 days. In addition, hardening was determined by whether the hydrogel was smeared and the hydrogel was stained on the nonwoven fabric.

Comparative Preparation Examples 2 to 8

(57) Cataplasms of Comparative Preparation Examples 2 to 8 were prepared in the same manner as in Example 1, except that the hydrogel resins of Comparative Examples 2 to 8 were used instead of the hydrogel resins of Example 1.

Experimental Example 1

Adhesion Measurement

(58) To investigate adhesion of the cataplasms prepared according to the preparation examples and the comparative preparation examples, 180° peel tests were performed. Results are shown in Tables 12 and 13 below. Adhesion was measured as follows: the peel layer was removed from the cataplasm, and then the cataplasm was cut into a size of a standard width of 12 mm and a length of 250 mm and was attached to a test plate with a width 12 mm and a length of 125 mm made of a phenol resin. A rubber roller with a mass of 850 g was rolled on the cataplasm twice at a speed of 300 mm for 1 minute such that the cataplasm was tightly attached to the test plate. Subsequently, the test plate was pulled out at a speed of 300 mm using a tensile strength tester (Instron 5544), and the load was measured four times at intervals of about 20 mm.

(59) TABLE-US-00012 TABLE 12 Classification Adhesion (gf) Preparation 70 Example 1 Preparation 64 Example 2 Preparation 61 Example 3 Preparation 71 Example 4 Preparation 64 Example 5 Preparation 60 Example 6 Preparation 71 Example 7 Preparation 63 Example 8 Preparation 68 Example 9 Preparation 61 Example 10 Preparation 72 Example 11 Preparation 61 Example 12 Preparation 81 Example 13 Preparation 68 Example 14 Preparation 62 Example 15 Preparation 95 Example 16 Preparation 85 Example 17 Preparation 69 Example 18 Preparation 79 Example 19 Preparation 76 Example 20 Preparation 68 Example 21 Preparation 64 Example 22 Preparation 63 Example 23 Preparation 61 Example 24 Preparation 58 Example 25 Preparation 58 Example 26 Preparation 57 Example 27 Preparation 60 Example 28 Preparation 65 Example 29 Preparation 68 Example 30 Preparation 60 Example 31 Preparation 58 Example 32 Preparation 65 Example 33 Preparation 62 Example 34 Preparation 60 Example 35 Preparation 68 Example 36 Preparation 63 Example 37 Preparation 61 Example 38 Preparation 63 Example 39 Preparation 62 Example 40 Preparation 64 Example 41 Preparation 53 Example 42 Preparation 55 Example 43 Preparation 56 Example 44 Preparation 62 Example 45 Preparation 65 Example 46 Preparation 68 Example 47 Preparation 56 Example 48 Preparation 58 Example 49 Preparation 63 Example 50 Preparation 56 Example 51 Preparation 57 Example 52 Preparation 55 Example 53 Preparation 58 Example 54 Preparation 57 Example 55 Preparation 61 Example 56 Preparation 63 Example 57 Preparation 64 Example 58 Preparation 63 Example 59 Preparation 61 Example 60 Preparation 60 Example 61 Preparation 63 Example 62 Preparation 70 Example 63 Preparation 71 Example 64 Preparation 73 Example 65 Preparation 71 Example 66 Preparation 72 Example 67 Preparation 68 Example 68 Preparation 67 Example 69 Preparation 70 Example 70 Preparation 65 Example 71 Preparation 67 Example 72 Preparation 69 Example 73 Preparation 68 Example 74 — —

(60) TABLE-US-00013 TABLE 13 Classification Adhesion (gf) Comparative 38 Preparation Example 1 Comparative x Preparation Example 2 Comparative 58 Preparation Example 3 Comparative 37 Preparation Example 4 Comparative 32 Preparation Example 5 Comparative 64 Preparation Example 6 Comparative x Preparation Example 7 Comparative x Preparation Example 8

(61) In the case of Comparative Example 2 using the hydrogel resin including less than 5% by weight of a hydrophilic polymer, Comparative Preparation Example 7 using the hydrogel resin excluding a UV initiator, and Comparative Preparation Example 8 using the hydrogel resin excluding a UV crosslinking agent, gel formation was not satisfactorily accomplished or crosslinking was not accomplished. Accordingly, it was impossible to measure adhesion.

(62) In addition, in the case of Comparative Preparation Example 4 including greater than 15% by weight of the active ingredient, a low adhesion of 37 gf, less than 50 gf, was observed. This result may be interpreted as being due to the excessively used active ingredient interfering with crosslinking and thus causing adhesion decrease of the hydrogel.

(63) Further, in the case of Comparative Preparation Example 5 including less than 0.6% by weight of the wetting agent, adhesion was very poor. This result may be interpreted as being due to excessive dryness of an attached portion of the UV-hardened hydrogel, which caused adhesion decrease.

Experimental Example 2

Measurement of Cumulative Skin Permeation Rate and Skin Permeation Speed

(64) The active ingredient in the drug layer of the cataplasm prepared according to Preparation Examples 1 to 74 and Comparative Preparation Examples 1 and 3 to 6 was subjected to cumulative skin permeation rate and skin permeation speed measurement experiments.

(65) A cumulative skin permeation rate was conducted under a sink condition under using a Franz diffusion cell (effective area: 0.64 cm.sup.2, the volume of an aqueous phase: 5.2 ml). More particularly, a Franz diffusion cell was filled with aqueous phosphate buffered saline (PBS) at pH 7.4 and the temperature thereof was maintained at 32±0.5° C., and then a sample was cut into a circle shape (area: 0.64 cm.sup.2) and was attached to the center of the prepared skin (human cadaver skin epidermis). The skin, to which the sample had been attached, was placed on the Franz diffusion cell, and then was covered with a doner and fixed with a clamp, followed by performing permeation experiments.

(66) A human cadaver skin epidermis layer for experimentation was purchased, and was used as the skin sample. The purchased human cadaver skin epidermis layer was stored at −70° C., and was used after thawing at 40° C. Active ingredient permeation analysis was conducted for 24 hours using HPLC. Results are summarized in Tables 14 and 15 below.

(67) TABLE-US-00014 TABLE 14 Cumulative skin Skin permeation permeation rate speed Classification (μg/cm.sup.2) (μg/cm.sup.2/hr) Preparation 55 ± 5.70 2.292 Example 1 Preparation 53 ± 5.84 2.208 Example 2 Preparation 51 ± 1.51 2.125 Example 3 Preparation 48 ± 2.81 2.000 Example 4 Preparation 57 ± 5.1  2.375 Example 5 Preparation 58 ± 5.07 2.417 Example 6 Preparation 60 ± 7.09 2.500 Example 7 Preparation 63 ± 3.19 2.625 Example 8 Preparation 57 ± 5.7  2.375 Example 9 Preparation 49 ± 5.1  2.042 Example 10 Preparation 57 ± 4.3  2.375 Example 11 Preparation 56 ± 9.1  2.333 Example 12 Preparation 55 ± 7.5  2.208 Example 13 Preparation 67 ± 5.74 2.208 Example 14 Preparation 54 ± 2.21 2.208 Example 15 Preparation 56 ± 2.71 2.208 Example 16 Preparation 57 ± 7.27 2.208 Example 17 Preparation 55 ± 7.75 2.208 Example 18 Preparation 48 ± 3.28 2.208 Example 19 Preparation 57 ± 7.87 2.208 Example 20 Preparation 67 ± 5.63 2.792 Example 21 Preparation 51 ± 3.93 2.125 Example 22 Preparation 57 ± 7.51 2.375 Example 23 Preparation 54 ± 7.34 2.250 Example 24 Preparation 56 ± 4.57 2.333 Example 25 Preparation 57 ± 7.12 2.375 Example 26 Preparation 61 ± 2.78 2.542 Example 27 Preparation 57 ± 7.3  2.208 Example 28 Preparation 58 ± 10.1 2.417 Example 29 Preparation 59 ± 7.2  2.458 Example 30 Preparation 62 ± 7.99 2.583 Example 31 Preparation 55 ± 5.12 2.292 Example 32 Preparation 57 ± 6.78 2.375 Example 33 Preparation 51 ± 2.78 2.125 Example 34 Preparation 53 ± 7.18 2.208 Example 35 Preparation 57 ± 2.07 2.375 Example 36 Preparation 56 ± 4.27 2.333 Example 37 Preparation 57 ± 3.93 2.208 Example 38 Preparation 54 ± 5.24 2.208 Example 39 Preparation 57 ± 7.91 2.208 Example 40 Preparation 55 ± 5.17 2.208 Example 41 Preparation 61 ± 3.87 2.208 Example 42 Preparation 57 ± 4.93 2.208 Example 43 Preparation 51 ± 4.78 2.208 Example 44 Preparation 49 ± 5.89 2.208 Example 45 Preparation 58 ± 5.14 2.417 Example 46 Preparation 53 ± 7.79 2.208 Example 47 Preparation 52 ± 7.12 2.167 Example 48 Preparation 51 ± 8.17 2.125 Example 49 Preparation 54 ± 5.42 2.250 Example 50 Preparation 51 ± 2.1  2.125 Example 51 Preparation 52 ± 3.45 2.167 Example 52 Preparation 57 ± 4.12 2.208 Example 53 Preparation 61 ± 3.78 2.542 Example 54 Preparation 57 ± 3.1  2.375 Example 55 Preparation 56 ± 7.12 2.333 Example 56 Preparation 72 ± 6.22 3.000 Example 57 Preparation 71 ± 5.81 2.958 Example 58 Preparation 75 ± 7.14 3.125 Example 59 Preparation 77 ± 7.37 3.208 Example 60 Preparation 81 ± 8.17 3.375 Example 61 Preparation 77 ± 7.57 3.208 Example 62 Preparation 94.96 ± 15.28   3.950 Example 63 Preparation 148 ± 9.03  6.610 Example 64 Preparation 51 ± 7.52 2.120 Example 65 Preparation 84.97 ± 2.32   3.540 Example 66 Preparation 84 ± 3.15 3.500 Example 67 Preparation 93 ± 4.55 3.875 Example 68 Preparation 81 ± 4.13 3.375 Example 69 Preparation  97 ± 17.13 4.040 Example 70 Preparation  81 ± 11.23 3.375 Example 71 Preparation 84 ± 9.12 3.500 Example 72 Preparation 86 ± 7.7  3.583 Example 73 Preparation 87 ± 3.14 3.625 Example 74 — — —

(68) TABLE-US-00015 TABLE 15 Cumulative skin permeation rate Skin permeation Classification (μg/cm.sup.2) speed (μg/cm.sup.2/hr) Comparative 6.28 ± 0.63   0.260 Preparation Example 1 Comparative 33 ± 1.52 1.181 Preparation Example 3 Comparative 79 ± 0.58 2.832 Preparation Example 4 Comparative 81 ± 1.13 3.375 Preparation Example 5 Comparative 12 ± 0.94 0.519 Preparation Example 6

(69) As shown in Table 13, it can be confirmed that the cataplasms of Preparation Examples 1 to 74 exhibit a cumulative skin permeation rate of 40 μg/cm.sup.2 or more and a skin permeation speed of 2.0 μg/cm.sup.2/hr or more.

(70) However, it can be confirmed that the conventional cataplasm of Comparative Preparation Example 1 prepared by metal complex ionic bonding exhibits a low cumulative skin permeation rate and a low skin permeation speed.

(71) In addition, it can be confirmed that Comparative Preparation Example 3 including greater than 60% by weight of the hydrophilic polymer exhibits excellent adhesion as shown in Table 12, but exhibits a low cumulative skin permeation rate and a low skin permeation speed compared to the preparation examples of Table 13. These results may be interpreted as occurring because the large amount of hydrophilic polymer forming crosslinks in the hydrogel rather deteriorates the skin permeation ability of the active ingredient.

(72) In addition, it can be confirmed that Comparative Preparation Example 4 including greater than 15% by weight of the active ingredient and Comparative Preparation Example 5 including less than 0.6% by weight of the wetting agent exhibit excellent cumulative skin permeation rate and skin permeation speed, but poor adhesion as shown in Table 12.

(73) In addition, it can be confirmed that Comparative Preparation Example 6 excluding the transdermal penetration facilitator exhibits excellent adhesion, but very poor cumulative skin permeation rate and skin permeation speed.

(74) From the results of the examples and experimental examples, it can be confirmed that the drug layer (hydrogel) in the cataplasm prepared using the hydrogel resin of the present invention has superior economic efficiency and marketability due to the high hardening speed thereof, excellent skin permeation ability and speed, and excellent adhesion to the skin. In addition, it is anticipated that the cataplasm of the present invention can be used to provide various pharmaceutical patches.

(75) Simple variations or modifications of the present invention may be readily practiced by those skilled in the art and all such modifications and variations are intended to be included within the scope of the present invention.